New York, NY, January 11, 2009 --(PR.com
)-- OrSense LTD, a privately held biointerventional cardiology company, announced today that it will participate in the OneMedPlace Finance Forum in San Francisco, CA from January 13-14, 2009. Lior Ma'ayan, CEO of OrSense, will present on Tuesday, January 13th at 11:30 a.m. Pacific Time, at the Sir Francis Drake Hotel at 450 Powell St. Information about the OneMedPlace Finance forum may be found at www.onemedplace.com.
OrSense develops non-invasive blood glucose monitoring products, as well as tools to non-invasively monitor critical blood parameters (such as hemoglobin and oxygen saturation). The company endeavors to significantly reduce the need for needle-stick blood tests.
OrSense's first product, the NBM-100, was granted CE approval and was submitted for FDA 510(k) and is a non-invasive blood glucose monitor, for both continuous and spot measurements. It allows self monitoring of blood glucose levels by people with diabetes. For more information, visit www.OrSense.com or contact the company at 9-728-946-5142.
About OneMedPlace: OneMedPlace is a virtual community of healthcare and life science companies. It has, for the first time, put in place the innovations that will shape the future of health and medicine—emerging companies and technologies seeking capital, distribution, visibility and resources to help finance, build and grow, and investors and strategic partners looking for health and medical innovations to invest in, acquire, license, distribute, purchase or utilize.